# Phase 2 Ischemic Stroke trials recruiting: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials in phase 2 for Ischemic Stroke that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Ischemic Stroke trials: 52 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/ischemic-stroke

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890298 | A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant | Lumosa Therapeutics Co., Ltd. | Phase 2 | Recruiting | Acute Ischemic Stroke | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890298) |
| September 28, 2026 | NCT07844603 | Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME) | University of Alberta | Phase 2 | Not yet recruiting | Acute Ischemic Stroke | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844603) |
| September 2, 2026 | NCT07800572 | Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2) | Capital Medical University | Phase 2 | Recruiting | Acute Ischemic Stroke | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800572) |
| August 10, 2026 | NCT07754825 | A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Not yet recruiting | Acute Ischemic Stroke | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754825) |
| August 3, 2026 | NCT07742098 | A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521... | NeuroTrauma Sciences, LLC | Phase 2 | Not yet recruiting | Acute Ischemic Stroke | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742098) |
| July 31, 2026 | NCT07739160 | The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 2 | Recruiting | Acute Ischemic Stroke | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739160) |
| July 17, 2026 | NCT07709845 | CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke | Clarion Cells, Inc. | Phase 2 | Not yet recruiting | Chronic Ischemic Stroke | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709845) |
| June 16, 2026 | NCT07651332 | A Study of Probiotics in Patients With Acute Ischemic Stroke | Capital Medical University | Phase 2 | Not yet recruiting | Ischemic Stroke | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651332) |
| June 12, 2026 | NCT07645560 | A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke | Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Ischemic Stroke | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645560) |
| May 12, 2026 | NCT07581210 | Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy | Shanghai QuietD Biotechnology Co., Ltd. | Phase 2 | Recruiting | Acute Ischemic Stroke | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581210) |
| April 24, 2026 | NCT07550296 | Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With... | General Hospital of Shenyang Military Region | Phase 2 | Recruiting | Acute Ischemic Stroke | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550296) |
| April 8, 2026 | NCT07516522 | Intra-arterial Methylprednisolone After Endovascular Thrombectomy | Tang-Du Hospital | Phase 2 | Recruiting | Ischemia Stroke, Thrombectomy, Large Vessel Occlusion | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516522) |
| April 6, 2026 | NCT07511543 | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Population Health Research Institute | Phase 2 | Not yet recruiting | Ischemic Stroke | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511543) |
| February 24, 2026 | NCT07430917 | Safety and Efficacy of J147 in Acute Ischemic Stroke | Abrexa Pharmaceuticals, Inc. | Phase 2 | Recruiting | Acute Ischemic Stroke | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430917) |
| February 20, 2026 | NCT07423975 | Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment... | Beijing Tiantan Hospital | Phase 2 | Recruiting | Stroke Acute, Endovascular Treatment | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423975) |
| February 17, 2026 | NCT07415655 | Modulation of Cerebral Ischemia by Albumin | University Hospital Hradec Kralove | Phase 2 | Recruiting | Ischemic Stroke | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415655) |
| February 12, 2026 | NCT07406971 | Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke | Instituto Mexicano del Seguro Social | Phase 2 | Recruiting | Ischemic Stroke | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406971) |
| February 9, 2026 | NCT07396337 | Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. | Changzhou Qianhong Bio-pharma Co., Ltd. | Phase 2 | Recruiting | Acute Ischemic Stroke | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396337) |
| February 6, 2026 | NCT07392450 | A Study of TAK-755 in Adults With Acute Ischemic Stroke | Takeda | Phase 2 | Recruiting | Acute Ischemic Stroke | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392450) |
| January 29, 2026 | NCT07375966 | Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With... | General Hospital of Shenyang Military Region | Phase 2 | Recruiting | Ischemic Stroke | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07375966) |
| January 29, 2026 | NCT07375953 | Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) | General Hospital of Shenyang Military Region | Phase 2 | Recruiting | Ischemic Stroke | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07375953) |
| January 26, 2026 | NCT07365475 | Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke | Tianjin Huanhu Hospital | Phase 2 | Not yet recruiting | Acute Ischemic Stroke From Large Vessel Occlusion | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365475) |
| December 29, 2025 | NCT07307989 | Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis | Chang Gung Memorial Hospital | Phase 2 | Recruiting | Ischemic Stroke, Hypercholesteremia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07307989) |
| December 19, 2025 | NCT07294391 | The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke | Tianjin Huanhu Hospital | Phase 2 | Not yet recruiting | Acute Ischemic Stroke From Large Vessel Occlusion | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294391) |
| December 15, 2025 | NCT07283159 | Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS) | General Hospital of Shenyang Military Region | Phase 2 | Recruiting | Ischemic Stroke | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283159) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Beijing Tiantan Hospital | 4 |
| General Hospital of Shenyang Military Region | 4 |
| University of Pennsylvania | 2 |
| Capital Medical University | 2 |
| [Shanghai Pharmaceuticals Holding Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-pharmaceuticals-holding-co-ltd) | 2 |
| Chang Gung Memorial Hospital | 2 |
| Tianjin Huanhu Hospital | 2 |
| University Hospital Hradec Kralove | 1 |
| Population Health Research Institute | 1 |
| NeuroTrauma Sciences, LLC | 1 |
| [Beijing Suncadia Pharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/beijing-suncadia-pharmaceuticals-co-ltd) | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| Changzhou Qianhong Bio-pharma Co., Ltd. | 1 |
| ThromBio Pty. Ltd. | 1 |
| Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd | 1 |
| Tang-Du Hospital | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| Hokkaido University Hospital | 1 |
| University of Milano Bicocca | 1 |
| Shenzhen Wingor Biotechnology Co., Ltd. | 1 |
| Aarhus University Hospital | 1 |
| Clarion Cells, Inc. | 1 |
| Lumosa Therapeutics Co., Ltd. | 1 |
| Shanghai IxCell Biotechnology Co., LTD | 1 |
| Shanghai QuietD Biotechnology Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 21 |
| United States | 7 |
| Canada | 4 |
| Australia | 3 |
| France | 2 |
| Germany | 2 |
| Japan | 2 |
| Taiwan | 2 |
| Czechia | 1 |
| Belgium | 1 |
| Brazil | 1 |
| Greece | 1 |
| India | 1 |
| United Kingdom | 1 |
| Italy | 1 |
| Denmark | 1 |
| Switzerland | 1 |
| Mexico | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [B2B environmental companies in the United States](https://specstream.ai/data/businesses/b2b-environmental-companies/united-states)
- [Property management companies in the United States](https://specstream.ai/data/businesses/property-management-companies/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
